(g) Yes, Sir.

(h) to (k) The required details to the extent available will be collected and laid on the Table of the House.

Price Control on drugs

132. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee reviewed the sales turn over of drugs in its supplementary report;

(b) if so, what are the names of drugs recommended for price decontrol on the basis of sales turn over of less than rupees fifty lacs;

(c) whether it is also a fact that his Ministry has not taken any action on these recommendations;

(d) if so, what are the details thereof;

(e) whether it is a fact that Kelkar Committee recommended for continuation of price control on certain drugs despite having sales turn over of less than rupees fifty lacs; and

(f) if so, the names of those drugs and special reasons for maintenance of price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The list is enclosed as Statement (*See* below). More details are given in the Supplementary Report of the Kelkar Committee copies of which are already available in the Parliament Library.

(c) to (f) The recommendations in this regard are yet to be examined and final decision taken.

Statement

Drugs having turn-over less than Rupees fifty lakhs in 1986.

Sl.	Name of the Bulk Drugs
1.	Amiloride
2.	Bephenium Hydroxy Napthoate
3.	Carbimazole
4.	Dehydroemetine
5.	Depamine
6.	Epinephrine
7.	Ethosuximide
8.	Ethionamide
9.	Flurazepam
10.	Glyceryl Trinitrate
11.	Heparin
12.	Hydralazine
13.	Hepatatis—B Vaccine
14.	Isoprenaline
15.	Nitrazepam
16.	Nitrofurantoin
17.	Primaquin
18.	Oxazepam
19.	Probenecid
20.	Protionamide
21.	Pentamidine
22.	Procainamide
23.	Quinidine
24.	Sulphadimidine

Sl.	Name of the Bulk Drug
25.	Sodium Nitroprusside
26.	Silver Nitrate
27.	Sodium Stibogluconate
28.	Tetramisole
29.	Thiabendazole
30.	Warfarin

Supplementary report of the Kelkar Committee

133. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the main report of the Kelkar Committee was made public immediately on submission;

(b) whether it is also a fact that supplementary report has not yet been made public despite the fact that it was submitted about six months back;

(c) whether it is a fact that the supplementary report is still full of contradictions and that is the main reason for withholding the same;

(d) whether it is a fact that Glybenclamide has been price decontrolled on the recommendation of Kelkar Committee;

(e) if so, on what ground and what are the names of other drugs which have been price decontrolled on some ground;

(f) whether it is a fact that his Ministry has not accepted all the recommendations of supplementary report; and

(g) if so, what are the details of recommendations still not accepted and what are the reasons for the same?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) The copies of the supplementary Report of the Kelkar Committee are already available in the Parliament Library.

(d) Yes, Sir.

(e) to (g) The required details are given in reply to Rajya Sabha Starred Question No. 77 answered on 27-2-1989.

Overcharging on Oxalgin, Dexona Tablets, Injections and drops

134. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) what are the approved prices of Oxalgin, Dexona Tablets, Injections and Drops and when was the price of each approved;

(b) what is the present price at which each of these products is being sold and since when;

(c) whether it is a fact that the poor consumer is being overcharged;

(d) whether it is also a fact that his Ministry is aware of over invoicing on imports of Dexamethasone and still no action has been taken; and

(e) by when the products would be made available to the consumer at reasonable prices?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details to the extent available are given in reply to Rajya Sabha Unstarred Question 151 for 24th April, 1989.